

Carmello Carlo-Stella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8686149/publications.pdf>

Version: 2024-02-01

280
papers

10,652
citations

61857

43
h-index

40881

93
g-index

289
all docs

289
docs citations

289
times ranked

14395
citing authors

#	ARTICLE	IF	CITATIONS
1	Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. <i>Blood</i> , 2002, 99, 3838-3843.	0.6	2,907
2	Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2000, 18, 1360-1377.	0.8	296
3	Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. <i>Blood</i> , 2015, 125, 1061-1072.	0.6	281
4	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1959-1970.	0.8	228
5	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 2413-2425.	0.6	223
6	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 790-800.	5.1	211
7	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. <i>Blood</i> , 2017, 129, 1380-1388.	0.6	209
8	Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). <i>Blood</i> , 2003, 102, 749-755.	0.6	193
9	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. <i>Nature Communications</i> , 2017, 8, 593.	5.8	175
10	Defective in vitro growth of the hemopoietic progenitor cells in the acquired immunodeficiency syndrome.. <i>Journal of Clinical Investigation</i> , 1987, 80, 286-293.	3.9	162
11	Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 724-729.	2.0	141
12	Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. <i>Blood</i> , 2015, 125, 2855-2864.	0.6	132
13	Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death. <i>Cancer Research</i> , 2010, 70, 9062-9072.	0.4	126
14	Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. <i>Transplant Infectious Disease</i> , 2015, 17, 242-249.	0.7	118
15	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2021, 137, 2634-2645.	0.6	111
16	Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation. <i>Blood</i> , 2000, 96, 3637-3643.	0.6	107
17	Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. <i>Blood</i> , 2009, 113, 18-27.	0.6	99
18	Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination. <i>Clinical Cancer Research</i> , 2004, 10, 5381-5390.	3.2	98

#	ARTICLE	IF	CITATIONS
19	Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3293-3299.	0.8	90
20	Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. <i>Leukemia</i> , 2003, 17, 1783-1793.	3.3	83
21	Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. <i>Blood</i> , 1987, 70, 1014-1019.	0.6	78
22	Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors. <i>Bone Marrow Transplantation</i> , 1997, 20, 465-471.	1.3	77
23	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 6986-6994.	3.2	77
24	Induction of apoptosis by arachidonic acid in chronic myeloid leukemia cells. <i>Cancer Research</i> , 1999, 59, 5047-53.	0.4	70
25	Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. <i>Blood</i> , 2009, 113, 4771-4779.	0.6	69
26	Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3K/Î³ Inhibitor RP6530. <i>Clinical Cancer Research</i> , 2019, 25, 1098-1112.	3.2	69
27	High-Dose Yttrium-90-Î² Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2008, 26, 5175-5182.	0.8	68
28	Targeting TRAIL Agonistic Receptors for Cancer Therapy. <i>Clinical Cancer Research</i> , 2007, 13, 2313-2317.	3.2	67
29	The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. <i>Haematologica</i> , 2008, 93, 1523-1534.	1.7	63
30	Therapy of molecular relapse in acute promyelocytic leukemia. <i>Blood</i> , 1999, 94, 2225-9.	0.6	61
31	Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. <i>Blood</i> , 2002, 100, 1104-1105.	0.6	58
32	Cell therapy: achievements and perspectives. <i>Haematologica</i> , 1999, 84, 1110-49.	1.7	54
33	Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. <i>Blood</i> , 1996, 88, 3091-3100.	0.6	53
34	Computed tomography (CT)-derived radiomic features differentiate prevascular mediastinum masses as thymic neoplasms versus lymphomas. <i>Radiologia Medica</i> , 2020, 125, 951-960.	4.7	52
35	Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, Tj ETQq1 1 0.784314 rgBT / Overlock 10	0.6	51
36	COVID-19-Induced endothelitis: emerging evidence and possible therapeutic strategies. <i>British Journal of Haematology</i> , 2021, 193, 43-51.	1.2	49

#	ARTICLE	IF	CITATIONS
37	Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone. <i>Experimental Hematology</i> , 2004, 32, 171-178.	0.2	48
38	BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. <i>Leukemia</i> , 2014, 28, 1861-1871.	3.3	48
39	Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. <i>Blood</i> , 2004, 103, 3287-3295.	0.6	47
40	Estrogen receptor β ligation inhibits Hodgkin lymphoma growth by inducing autophagy. <i>Oncotarget</i> , 2017, 8, 8522-8535.	0.8	47
41	Germâ€line mutation of the <i>NRAS</i> gene may be responsible for the development of juvenile myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2009, 147, 706-709.	1.2	46
42	T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 627-632.	2.0	46
43	CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. <i>Blood Advances</i> , 2020, 4, 3850-3852.	2.5	46
44	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	3.3	45
45	Effects of the Tyrosine Kinase Inhibitor AG957 and an Anti-Fas Receptor Antibody on CD34+ Chronic Myelogenous Leukemia Progenitor Cells. <i>Blood</i> , 1999, 93, 3973-3982.	0.6	44
46	Role of alpha-synuclein in autophagy modulation of primary human T lymphocytes. <i>Cell Death and Disease</i> , 2014, 5, e1265-e1265.	2.7	43
47	Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes. <i>Shock</i> , 2022, 57, 95-105.	1.0	43
48	Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B-cell hematologic malignancies. <i>Cell Death and Disease</i> , 2013, 4, e863-e863.	2.7	42
49	Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2017, 52, 683-688.	1.3	42
50	Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilarâ€treated IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1181-1187.	1.9	42
51	Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. <i>Bone Marrow Transplantation</i> , 2014, 49, 1475-1480.	1.3	41
52	FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradationâ€Induced Mitochondrial Oxidative Stress. <i>Cancer Research</i> , 2020, 80, 2340-2354.	0.4	41
53	Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. <i>Experimental Hematology</i> , 2005, 33, 920-927.	0.2	40
54	Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor-alpha: evidence for a tyrosine-kinase-dependent process. <i>Blood</i> , 1995, 86, 2967-2975.	0.6	38

#	ARTICLE	IF	CITATIONS
55	The Anti- α -Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3 Activates the Mitochondrial Cell Death Pathway and Exerts a Potent Antitumor Activity in Lymphoma-Bearing Nonobese Diabetic/Severe Combined Immunodeficient Mice. <i>Cancer Research</i> , 2006, 66, 1799-1808.	0.4	37
56	Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation. <i>Blood</i> , 2000, 96, 3637-43.	0.6	37
57	Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor. <i>Leukemia Research</i> , 2002, 26, 1131-1133.	0.4	36
58	Phase II study of sorafenib in patients with relapsed or refractory lymphoma. <i>British Journal of Haematology</i> , 2012, 158, 108-119.	1.2	36
59	High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. <i>British Journal of Haematology</i> , 2004, 126, 815-820.	1.2	35
60	Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?. <i>Blood</i> , 2018, 132, 17-22.	0.6	35
61	Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies. <i>Leukemia</i> , 1989, 3, 104-7.	3.3	35
62	Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. <i>Leukemia and Lymphoma</i> , 2010, 51, 1251-1259.	0.6	34
63	Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells. <i>PLoS ONE</i> , 2013, 8, e61603.	1.1	34
64	Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients. <i>Blood</i> , 1994, 83, 1373-1380.	0.6	33
65	Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors. <i>Blood</i> , 1995, 86, 3387-3393.	0.6	33
66	CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF. <i>Bone Marrow Transplantation</i> , 1998, 21, 561-568.	1.3	33
67	Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cells. <i>Biochemical Pharmacology</i> , 2002, 63, 967-975.	2.0	33
68	Antitumor Activity of Human CD34+ Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. <i>Human Gene Therapy</i> , 2006, 17, 1225-1240.	1.4	33
69	Primitive hematopoietic progenitors within mobilized blood are spared by uncontrolled rate freezing. <i>Bone Marrow Transplantation</i> , 1999, 23, 497-503.	1.3	32
70	Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature. <i>Blood</i> , 2010, 115, 2231-2240.	0.6	32
71	Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis. <i>Investigational New Drugs</i> , 2011, 29, 1264-1275.	1.2	31
72	Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. <i>Clinical Cancer Research</i> , 2014, 20, 5641-5651.	3.2	31

#	ARTICLE	IF	CITATIONS
73	Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. <i>British Journal of Haematology</i> , 2014, 166, 140-142.	1.2	31
74	Clonogenic capacity and <i>ex vivo</i> expansion potential of umbilical cord blood progenitor cells are not impaired by cryopreservation. <i>Bone Marrow Transplantation</i> , 1997, 19, 1079-1084.	1.3	30
75	DNA damage by tobacco smoke and some antitubercular drugs evaluated using the Comet assay. <i>Toxicology Letters</i> , 1999, 108, 267-276.	0.4	30
76	Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF. <i>Leukemia</i> , 2005, 19, 644-651.	3.3	30
77	Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. <i>Blood</i> , 2011, 118, 4421-4430.	0.6	30
78	The Role of Inflammation in Lymphoma. <i>Advances in Experimental Medicine and Biology</i> , 2014, 816, 315-333.	0.8	30
79	Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. <i>Journal of Pathology</i> , 2015, 237, 4-13.	2.1	30
80	Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5503.	1.8	30
81	Brentuximab Vedotin in Patients With Hodgkin Lymphoma and a Failed Allogeneic Stem Cell Transplantation: Results From a Named Patient Program at Four Italian Centers. <i>Oncologist</i> , 2015, 20, 323-328.	1.9	29
82	YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation. <i>International Journal of Cancer</i> , 2015, 136, 299-309.	2.3	29
83	Complete remission of follicular lymphoma after SARS-CoV-2 infection: from the "flare phenomenon" to the "abscopal effect". <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2652-2654.	3.3	29
84	mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients. <i>Life Science Alliance</i> , 2022, 5, e202201381.	1.3	29
85	Role of Apollon in Human Melanoma Resistance to Antitumor Agents That Activate the Intrinsic or the Extrinsic Apoptosis Pathways. <i>Clinical Cancer Research</i> , 2012, 18, 3316-3327.	3.2	27
86	Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 136-140.	2.5	27
87	In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte-macrophage colony-stimulating factor. <i>Bone Marrow Transplantation</i> , 1991, 8, 265-73.	1.3	27
88	Immune reconstitution after in utero bone marrow transplantation in a fetus with severe combined immunodeficiency with natural killer cells. <i>Transplantation Proceedings</i> , 1999, 31, 2581.	0.3	26
89	Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts. <i>Leukemia</i> , 2013, 27, 1677-1687.	3.3	26
90	CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. <i>Experimental Hematology</i> , 2006, 34, 721-727.	0.2	25

#	ARTICLE	IF	CITATIONS
91	Long-term lymphoma survivors following high-dose chemotherapy and autograft: Evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir. <i>Experimental Hematology</i> , 2007, 35, 673-681.	0.2	25
92	High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. <i>Bone Marrow Transplantation</i> , 2009, 43, 509-511.	1.3	25
93	Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor. <i>Leukemia and Lymphoma</i> , 2014, 55, 331-336.	0.6	25
94	Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. <i>Bone Marrow Transplantation</i> , 1994, 14, 425-32.	1.3	25
95	Density separation of umbilical cord blood and recovery of hemopoietic progenitor cells: Implications for cord blood banking. <i>Stem Cells</i> , 1995, 13, 533-540.	1.4	24
96	CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial. <i>Blood</i> , 2018, 132, 226-226.	0.6	24
97	Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial. <i>Blood</i> , 2019, 134, 1584-1584.	0.6	24
98	Biologic and phenotypic analysis of early hematopoietic progenitor cells in umbilical cord blood. <i>Leukemia</i> , 1997, 11, 2143-2149.	3.3	23
99	Amifostine (WR-2721) selective protection against melphalan genotoxicity. <i>Leukemia</i> , 2000, 14, 1642-1651.	3.3	23
100	Myeloablative doses of yttrium-90-labeled anti-CD22 antibody and the risk of secondary myelodysplasia/acute myelogenous leukemia. <i>Cancer</i> , 2011, 117, 5074-5084.	2.0	23
101	The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2016, 51, 1134-1136.	1.3	23
102	The Many Facets of CD38 in Lymphoma: From Tumor Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy. <i>Cells</i> , 2020, 9, 802.	1.8	23
103	Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells. <i>British Journal of Haematology</i> , 1996, 93, 551-557.	1.2	22
104	Immunization of Patients with Malignant Melanoma with Autologous CD34+Cell-Derived Dendritic Cells Transduced Ex Vivo with a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial. <i>Human Gene Therapy</i> , 2003, 14, 1347-1360.	1.4	22
105	Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders. <i>FASEB Journal</i> , 2014, 28, 524-535.	0.2	22
106	T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2016, 51, 194-198.	1.3	22
107	Forced expression of RDH10 gene retards growth of HepG2 cells. <i>Cancer Biology and Therapy</i> , 2007, 6, 238-245.	1.5	21
108	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	1.3	21

#	ARTICLE	IF	CITATIONS
109	Growth of CD34+ acute myeloblastic leukemia colony-forming cells in response to recombinant hematopoietic growth factors. <i>Leukemia</i> , 1990, 4, 561-6.	3.3	21
110	Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. <i>Blood</i> , 1987, 70, 1014-9.	0.6	21
111	Acquired cyclic thrombocytopenia <thr< th="">ombocytosis with periodic defect of platelet function. <i>British Journal of Haematology</i>, 1993, 85, 718-722.</thr<>	1.2	20
112	Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma. <i>Cell Death and Disease</i> , 2014, 5, e1434-e1434.	2.7	20
113	Expanded circulating hematopoietic stem/progenitor cells as novel cell source for the treatment of TCIRG1 osteopetrosis. <i>Haematologica</i> , 2020, 106, 74-86.	1.7	20
114	Growth of human hematopoietic colonies from patients with myelodysplastic syndromes in response to recombinant human granulocyte-macrophage colony-stimulating factor. <i>Leukemia</i> , 1989, 3, 363-6.	3.3	20
115	Selective expression and constitutive phosphorylation of SHC proteins [corrected] in the CD34+ fraction of chronic myelogenous leukemias. <i>Cancer Research</i> , 2000, 60, 728-32.	0.4	20
116	Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow. <i>Blood</i> , 1992, 80, 2412-2418.	0.6	19
117	Specific Histone Patterns and Acetylase/Deacetylase Activity at the Breakpoint-Cluster Region of the Human MLL Gene. <i>Cancer Research</i> , 2004, 64, 2656-2662.	0.4	19
118	Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkinâ€™s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1745-1757.	3.3	19
119	A First-in-human Study of Tenalisib (RP6530), a Dual PI3K Î³/Î² Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 78-86.	0.2	19
120	IFN-Î³ Enhances the Antimyeloma Activity of the Fully Human Antiâ€‘Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3. <i>Cancer Research</i> , 2007, 67, 3269-3275.	0.4	18
121	Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation. <i>Scientific Reports</i> , 2016, 6, 35745.	1.6	18
122	Large-scale feasibility of gene transduction into human CD34+ cell-derived dendritic cells by adenoviral/polycation complex. <i>British Journal of Haematology</i> , 2000, 111, 344-350.	1.2	18
123	Umbilical cord blood as a source of hematopoietic stem cells: from research to clinical application. <i>Haematologica</i> , 1995, 80, 473-9.	1.7	18
124	Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice. <i>Cancer Research</i> , 2002, 62, 6152-7.	0.4	18
125	Recombinant Adenoviral Vector-LipofectAMINE Complex for Gene Transduction into Human T Lymphocytes. <i>Human Gene Therapy</i> , 1999, 10, 1875-1884.	1.4	17
126	Peripheral blood progenitor cell mobilization in healthy donors receiving recombinant human granulocyte colony-stimulating factor. <i>Experimental Hematology</i> , 2000, 28, 216-224.	0.2	17

#	ARTICLE	IF	CITATIONS
127	High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. <i>Annals of Oncology</i> , 2015, 26, 167-172.	0.6	17
128	CD20-TCB (RG6026), A NOVEL $\alpha 2:1$ ϵ -FORMAT T-CELL-ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 92-93.	0.8	16
129	Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 21-23.	0.6	16
130	Treatment of Hodgkin Lymphoma Xenografts with the Novel PI3K γ Inhibitor RP6530 Suppresses M2 Macrophage Polarization and Results in Potent Antitumor and Antiangiogenic Effects. <i>Blood</i> , 2016, 128, 45-45.	0.6	16
131	Effects of recombinant human H-subunit and L-subunit ferritins on in vitro growth of human granulocyte-monocyte progenitors. <i>British Journal of Haematology</i> , 1988, 68, 367-372.	1.2	15
132	T-lymphocyte function after retroviral-mediated thymidine kinase gene transfer and G418 selection. <i>Cancer Gene Therapy</i> , 2000, 7, 920-926.	2.2	15
133	Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with ^{13}C cytokines. <i>Blood</i> , 2006, 107, 602-609.	0.6	15
134	Peripheral Blood Stem Cells versus Bone Marrow for T Cell "Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1810-1817.	2.0	15
135	Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts. <i>The Hematology Journal</i> , 2001, 2, 70-80.	2.0	15
136	Density Separation and Cryopreservation of Umbilical Cord Blood Cells: Evaluation of Recovery in Short- and Long-Term Cultures. <i>Acta Haematologica</i> , 1996, 95, 171-175.	0.7	14
137	Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status. <i>Bone Marrow Transplantation</i> , 2010, 45, 505-512.	1.3	14
138	Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose γ -lirbitumomab Tixetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. <i>Journal of Clinical Oncology</i> , 2013, 31, 2974-2976.	0.8	14
139	CURRENT ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015, 7, e2015015.	0.5	14
140	B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY. <i>Bone Marrow Transplantation</i> , 2015, 50, 317-319.	1.3	14
141	Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction. <i>Radiation Oncology</i> , 2020, 15, 12.	1.2	14
142	Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation. <i>Experimental Hematology</i> , 1992, 20, 328-33.	0.2	14
143	Ex vivo expansion of hematopoietic cells and their clinical use. <i>Haematologica</i> , 1998, 83, 824-48.	1.7	14
144	New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia. <i>Haematologica</i> , 1999, 84, 369-72.	1.7	14

#	ARTICLE	IF	CITATIONS
145	The novel PI3K-Î inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. <i>Leukemia</i> , 2016, 30, 2402-2405.	3.3	13
146	MicroRNA-127-3p controls murine hematopoietic stem cell maintenance by limiting differentiation. <i>Haematologica</i> , 2019, 104, 1744-1755.	1.7	13
147	Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. <i>Cancer Medicine</i> , 2020, 9, 52-61.	1.3	13
148	Preliminary Results of a Phase II Trial with the Multikinase Inhibitor Sorafenib in Heavily Pretreated Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2009, 114, 1658-1658.	0.6	13
149	Methodological framework for radiomics applications in Hodgkin's lymphoma. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 9.	0.6	13
150	Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside. <i>Haematologica</i> , 2006, 91, 255-7.	1.7	13
151	Placental Growth Factor-1 Potentiates Hematopoietic Progenitor Cell Mobilization Induced by Granulocyte Colony-Stimulating Factor in Mice and Nonhuman Primates. <i>Stem Cells</i> , 2007, 25, 252-261.	1.4	12
152	A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments. <i>Laboratory Investigation</i> , 2009, 89, 1063-1070.	1.7	12
153	Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients. <i>BMC Cancer</i> , 2020, 20, 1140.	1.1	12
154	Autologous bone marrow transplantation in acute myelogenous leukemia. <i>Leukemia</i> , 1992, 6, 1101-6.	3.3	12
155	Stem cell purging: an intriguing dilemma. <i>Experimental Hematology</i> , 1995, 23, 296-302.	0.2	12
156	Chemotherapy after $PD-1$ inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics. <i>British Journal of Haematology</i> , 2022, 198, 82-92.	1.2	12
157	Establishment and characterization of a B-cell line derived from a patient with a myelodysplastic syndrome which expresses myelomonocytic and lymphoid markers. <i>British Journal of Haematology</i> , 1991, 78, 167-172.	1.2	11
158	Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before "replete haploidentical transplantation. <i>Transfusion</i> , 2016, 56, 1096-1100.	0.8	11
159	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2017, 102, 1931-1935.	1.7	11
160	Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection. <i>Haematologica</i> , 2003, 88, 1396-404.	1.7	11
161	Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. <i>Bone Marrow Transplantation</i> , 2014, 49, 485-491.	1.3	10
162	Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma. <i>Biomarkers in Medicine</i> , 2015, 9, 807-817.	0.6	10

#	ARTICLE	IF	CITATIONS
163	Response to Maccio et al, "Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?" Journal of Thrombosis and Haemostasis, 2020, 18, 3111-3113.	1.9	10
164	Copanlisib for the treatment of adults with relapsed follicular lymphoma. Expert Review of Clinical Pharmacology, 2020, 13, 813-823.	1.3	10
165	Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study. HemaSphere, 2020, 4, e302.	1.2	10
166	Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome. Bone Marrow Transplantation, 2021, 56, 883-889.	1.3	10
167	Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor-alpha: evidence for a tyrosine-kinase-dependent process. Blood, 1995, 86, 2967-2975.	0.6	10
168	Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Blood, 1996, 88, 3091-100.	0.6	10
169	Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts. The Hematology Journal, 2001, 2, 70-80.	2.0	10
170	Techniques for Detection of Minimal Residual Disease. Leukemia and Lymphoma, 1995, 18, 75-80.	0.6	9
171	Retroviral transfer of herpes simplex virus-thymidine kinase and beta-galactosidase genes into U937 cells with bicistronic vector. Leukemia Research, 1997, 21, 951-959.	0.4	9
172	Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up. Bone Marrow Transplantation, 2010, 45, 1119-1120.	1.3	9
173	Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment. Mechanisms of Ageing and Development, 2012, 133, 479-488.	2.2	9
174	D Quantification of Tumor Vasculature in Lymphoma Xenografts in NOD/SCID Mice Allows to Detect Differences among Vascular-Targeted Therapies. PLoS ONE, 2013, 8, e59691.	1.1	9
175	High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. Bone Marrow Transplantation, 2015, 50, 499-504.	1.3	9
176	Planned Interim Analysis of a Phase 2 Study of Loncastuximab Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma (LOTIS-3). Blood, 2021, 138, 54-54.	0.6	9
177	Stem cell manipulation: why and how performing peripheral blood progenitor cell purging. Critical Reviews in Oncology/Hematology, 1997, 26, 101-115.	2.0	8
178	Chronic myeloid leukemia in first chronic phase not responding to \pm -interferon: outcome and prognostic factors after autologous transplantation. Bone Marrow Transplantation, 1999, 24, 259-264.	1.3	8
179	Plerixafor "on demand"™: results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF. Bone Marrow Transplantation, 2014, 49, 453-455.	1.3	8
180	High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Promising Activity, Minimal Toxicity and Full Feasibility in an Outpatient Setting.. Blood, 2006, 108, 3047-3047.	0.6	8

#	ARTICLE	IF	CITATIONS
181	Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study. <i>Blood</i> , 2011, 118, 1647-1647.	0.6	8
182	Tumor necrosis factor alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia. <i>Leukemia</i> , 1990, 4, 426-30.	3.3	8
183	Counterflow centrifugal elutriation: present and future. <i>Bone Marrow Transplantation</i> , 1993, 12, 105-8.	1.3	8
184	Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells. <i>Leukemia</i> , 1998, 12, 434-440.	3.3	7
185	Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor. <i>Experimental Hematology</i> , 2004, 32, 68-75.	0.2	7
186	Biology and clinical applications of marrow mesenchymal stem cells. <i>Pathologie Et Biologie</i> , 2005, 53, 162-164.	2.2	7
187	Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. <i>Haematologica</i> , 2015, 100, e423-e427.	1.7	7
188	The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2019, 54, 1164-1167.	1.3	7
189	Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1144-1153.	3.3	7
190	Nonmyeloablative Conditioning Regimen Including Low-Dose Total Marrow/Lymphoid Irradiation Before Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Advanced Lymphoproliferative Diseases. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 492.e1-492.e6.	0.6	7
191	Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 757-757.	0.6	7
192	Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow. <i>Bone Marrow Transplantation</i> , 1995, 16, 95-101.	1.3	7
193	BCL2 oncogene protein expression in human hematopoietic precursors during fetal life. <i>Experimental Hematology</i> , 1996, 24, 459-65.	0.2	7
194	THE ANTIBODY-DRUG CONJUGATE LONCASTUXIMAB TESIRINE FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA. <i>Blood</i> , 2022, , .	0.6	7
195	Transforming growth factor β 3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis. <i>Experimental Hematology</i> , 2000, 28, 775-783.	0.2	6
196	Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2016, 51, 462-465.	1.3	6
197	Caspofungin for primary antifungal prophylaxis after β 3-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide. <i>European Journal of Haematology</i> , 2019, 102, 357-367.	1.1	6
198	<p>Salvage Therapy for Hodgkin’s Lymphoma: A Review of Current Regimens and Outcomes</p>. <i>Journal of Blood Medicine</i> , 2020, Volume 11, 389-403.	0.7	6

#	ARTICLE	IF	CITATIONS
199	Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 423-433.	1.5	6
200	Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial. <i>Blood</i> , 2012, 120, 3679-3679.	0.6	6
201	Response to cyclosporin A and recombinant human erythropoietin in a case of B cell chronic lymphocytic leukemia and pure red cell aplasia. <i>Leukemia</i> , 1996, 10, 1400-1.	3.3	6
202	Genetic Idiotypic and Tumor Cell-Based Vaccine Strategies for Indolent Non Hodgkins Lymphoma. <i>Current Gene Therapy</i> , 2005, 5, 511-521.	0.9	5
203	Highly efficient gene transfer into mobilized CD34+ hematopoietic cells using serotype-5 adenoviral vectors and BoosterExpress Reagent. <i>Experimental Hematology</i> , 2007, 35, 888-897.	0.2	5
204	Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34+ cells. <i>Angiogenesis</i> , 2013, 16, 707-722.	3.7	5
205	Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors. <i>Scientific Reports</i> , 2018, 8, 17520.	1.6	5
206	Longitudinal Assessment of Circulating Tumor Mutational Burden Using a Next-Generation Sequencing Cancer Gene Panel: A Potential Biomarker of Response to Programmed Cell Death 1 (PD-1) Blockade in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 131-131.	0.6	5
207	High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Minimal Toxicity and Full Feasibility in an Outpatient Setting.. <i>Blood</i> , 2005, 106, 2737-2737.	0.6	5
208	Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Meclorothamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed/Refractory Hodgkin Lymphoma (HL). <i>Blood</i> , 2008, 112, 2586-2586.	0.6	5
209	Tumor necrosis factor alpha modulates the messenger RNA expression of hematopoietic growth factor genes in fresh blast cells from patients with acute myeloblastic leukemia. <i>Leukemia</i> , 1991, 5, 886-91.	3.3	5
210	In vitro and in vivo effects of recombinant interferon gamma on the growth of hematopoietic progenitor cells from patients with myelodysplastic syndrome. <i>Haematologica</i> , 1989, 74, 435-40.	1.7	5
211	Biology and Clinical Applications of Longterm Bone Marrow Cultures. <i>International Journal of Artificial Organs</i> , 1993, 16, 76-79.	0.7	4
212	Radioimmunotherapy and secondary leukemia: A case report. <i>Leukemia Research</i> , 2010, 34, e1-e4.	0.4	4
213	Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 1644-1646.	1.3	4
214	SAFETY AND CLINICAL ACTIVITY OF RP6530, A DUAL PI3K $\hat{\imath}$ / $\hat{\imath}$ 3 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES: FINAL ANALYSIS OF A PHASE 1 MULTI-CENTER STUDY. <i>Hematological Oncology</i> , 2017, 35, 263-263.	0.8	4
215	ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT-402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 93-95.	0.8	4
216	Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2299-2305.	2.0	4

#	ARTICLE	IF	CITATIONS
217	A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Investigational New Drugs</i> , 2021, 39, 1028-1035.	1.2	4
218	Generation of an immunodeficient mouse model of tcirg1-deficient autosomal recessive osteopetrosis. <i>Bone Reports</i> , 2020, 12, 100242.	0.2	4
219	In vitro growth of bone marrow-derived multipotent and lineage-restricted hematopoietic progenitor cells in myelodysplastic syndromes. <i>Haematologica</i> , 1989, 74, 181-6.	1.7	4
220	Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM,) Tj ETQq0 0 0 rgBTdOverlock410 Tf 50 6	0.4	3
221	Stem cells and stem cell transplantation. <i>Haematologica</i> , 1996, 81, 573-87.	1.7	4
222	Gamma-rays from MÃ¶ssbauer sources: a low-dose approach to cancer therapy. <i>Nuovo Cimento Della Societa Italiana Di Fisica D - Condensed Matter, Atomic, Molecular and Chemical Physics, Biophysics</i> , 1992, 14, 351-358.	0.4	3
223	Fractionation of Chronic Myelogenous Leukemia Marrow Cells by Stroma Adherence: Implications for Marrow Purging. <i>Leukemia and Lymphoma</i> , 1993, 11, 109-112.	0.6	3
224	Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells. <i>Stem Cells</i> , 1993, 11, 170-174.	1.4	3
225	In Vitro Growth of Mobilized Peripheral Blood Progenitor Cells is Significantly Enhanced by Stem Cell Factor. <i>Stem Cells</i> , 1997, 15, 207-213.	1.4	3
226	In Vitro Manipulation of Peripheral Blood Progenitor Cell Collections. <i>International Journal of Artificial Organs</i> , 1998, 21, 1-10.	0.7	3
227	Predictors of CD34+ Cell Mobilization and Collection in Adult Men With Germ Cell Tumors: Implications for the Salvage Treatment Strategy. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 196-202.e1.	0.9	3
228	A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a <scp>HLA</scp> identical sibling. <i>Transplant Infectious Disease</i> , 2018, 20, e12906.	0.7	3
229	Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 366-370.	1.3	3
230	Anticancer Cell Therapy with TRAIL-Armed CD34+ Progenitor Cells. <i>Advances in Experimental Medicine and Biology</i> , 2008, 610, 100-111.	0.8	3
231	Clinical Activity and Safety of RP6530, a Dual PI3KÎ³ Inhibitor, in Patients with Advanced Hematologic Malignancies: Final Analysis of a Phase 1 Multicenter Study. <i>Blood</i> , 2016, 128, 3011-3011.	0.6	3
232	Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. <i>Blood</i> , 1987, 70, 1014-1019.	0.6	3
233	Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow. <i>Blood</i> , 1992, 80, 2412-8.	0.6	3
234	Human peripheral blood mononuclear cell subfractionation using counterflow centrifugation elutriation. <i>Haematologica</i> , 1991, 76, 89-93.	1.7	3

#	ARTICLE	IF	CITATIONS
235	Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells. <i>Blood</i> , 1999, 93, 3973-82.	0.6	3
236	Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e738-e744.	0.2	3
237	Hematopoietic growth factors: In vitro and in vivo studies in bone marrow transplantation. <i>International Journal of Cell Cloning</i> , 1990, 8, 270-278.	1.6	2
238	Autologous transplantation for chronic myelogenous leukemia with mafosfamide‐treated marrow. <i>Stem Cells</i> , 1993, 11, 25-30.	1.4	2
239	The strange case of the lost <i>NRAS</i> mutation in a child with juvenile myelomonocytic leukemia. <i>Pediatric Blood and Cancer</i> , 2012, 59, 580-582.	0.8	2
240	DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA (HD): RESULTS OF A PHASE II, PROSPECTIVE STUDY BY FONDAZIONE ITALIANA LINFOMI. <i>Hematological Oncology</i> , 2019, 37, 291-292.	0.8	2
241	Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis Lymphomas. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 328.e1-328.e6.	0.6	2
242	Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Treatment in Dual Expressor Diffuse Large B-Cell and Double/Triple Hit Lymphomas: TP53 Mutations Influence on Clinical Outcome. <i>Blood</i> , 2019, 134, 4116-4116.	0.6	2
243	In Vitro and In Vivo Anti-Lymphoma Activity of the Anti-HLA-DR Monoclonal Antibody 1D09C3. <i>Blood</i> , 2004, 104, 3285-3285.	0.6	2
244	Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity. <i>Blood</i> , 2010, 116, 3375-3375.	0.6	2
245	Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients. <i>Blood</i> , 1994, 83, 1373-80.	0.6	2
246	Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM,) Tj ETQq0 0 0 rgBTd Overlock 210 Tf 50 2		
247	Effects of MÃ¶ssbauer radiation on bone marrow cultures. <i>Hyperfine Interactions</i> , 1992, 71, 1267-1270.	0.2	1
248	Two Phase I Open-Label Studies of the Fully Human HLA-DR-Specific IgG4 Monoclonal Antibody 1D09C3 in Patients with Relapsed and/or Refractory B-Cell Lymphoproliferative Neoplasias on a Weekly and Bi-Weekly Dosing Scheme. <i>Blood</i> , 2006, 108, 2730-2730.	0.6	1
249	Effects of the Tyrosine Kinase Inhibitor AG957 and an Anti-Fas Receptor Antibody on CD34+ Chronic Myelogenous Leukemia Progenitor Cells. <i>Blood</i> , 1999, 93, 3973-3982.	0.6	1
250	Limited engraftment capacity of bone marrowâ€derived mesenchymal cells following T-cellâ€depleted hematopoietic stem cell transplantation. <i>Blood</i> , 2000, 96, 3637-3643.	0.6	1
251	Identification of Philadelphia-negative granulocyte-macrophage colony- forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients. <i>Blood</i> , 1994, 83, 1373-1380.	0.6	1
252	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. <i>Blood</i> , 2020, 136, 6-8.	0.6	1

#	ARTICLE	IF	CITATIONS
253	Biology and clinical applications of long-term bone marrow cultures. International Journal of Artificial Organs, 1993, 16 Suppl 5, 76-9.	0.7	1
254	Inactivation of bone marrow cultures and K562 leukaemic cell line by MÄ¶ssbauer effect. Anticancer Research, 1998, 18, 419-23.	0.5	1
255	Recurrence-specific supervised graph clustering for subtyping Hodgkin Lymphoma radiomic phenotypes. , 2021, 2021, 2155-2158.		1
256	Purging the Bone Marrow in Non-Hodgkin's Lymphomas. Is There Any Evidence of its Value?. Leukemia and Lymphoma, 1992, 7, 7-10.	0.6	0
257	Biological aspects and clinical results of autologous bone marrow transplantation for acute myeloid leukemia. International Journal of Clinical and Laboratory Research, 1992, 22, 185-189.	1.0	0
258	Biological and chemical selection of ph‐negative clones. Stem Cells, 1993, 11, 77-82.	1.4	0
259	High-Dose Therapy in Acute Leukemia. Leukemia and Lymphoma, 1997, 26, 61-67.	0.6	0
260	Large-scale feasibility of gene transduction into human CD34⁺ cell-derived dendritic cells by adenoviral/polycation complex. British Journal of Haematology, 2000, 111, 344-350.	1.2	0
261	Artificial Antigen Presenting Cells With Preclustered anti-CD28/-CD3/-LFA-1 Monoclonal Antibodies Are Highly Effective To Induce The Ex-Vivo Expansion Of Functional Human Antitumor T Cells. Nature Precedings, 2007, , .	0.1	0
262	Recent Advancements in Hematology: Knowledge, Methods and Dissemination. Hemato, 2020, 1, 5-6.	0.2	0
263	Primary Plasma Cells Expressing CD52 Are Efficiently Targeted In Vivo by Alemtuzumab.. Blood, 2004, 104, 3460-3460.	0.6	0
264	Antitumor Activity of Human CD34+Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Human Gene Therapy, 2006, .	1.4	0
265	Interferon Î³ Enhances the Anti-Myeloma Activity of the Fully Human Anti-HLA-DR Monoclonal Antibody 1D09C3.. Blood, 2006, 108, 656-656.	0.6	0
266	Human CD34+ Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Exert a Potent Anti-Lymphoma Effects by Targeting Tumor Vasculature.. Blood, 2007, 110, 527-527.	0.6	0
267	Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib In Heavily Pretreated Patients with Relapsed/Refractory Lymphomas: Preliminary Results of a Phase II Trial. Blood, 2010, 116, 2861-2861.	0.6	0
268	Phosphorylation Levels of Extracellular-Signal Regulated Kinase (ERK) and AKT in Circulating Lymphocytes Predict Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients.. Blood, 2011, 118, 3705-3705.	0.6	0
269	Preclinical Rationale for the Use of the Combined Treatment with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin Lymphoma. Blood, 2011, 118, 1653-1653.	0.6	0
270	Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma After High Dose Chemotherapy and or Allogeneic Transplant: A Study of Fondazione Italiana Linfomi (FIL). Blood, 2012, 120, 3652-3652.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow. <i>Blood</i> , 1992, 80, 2412-2418.	0.6	0
272	Shc Overexpression Induces Selective Hypersensitivity to GM-CSF and Prevents Apoptosis of the GM-CSF-Dependent Acute Myelogenous Leukemia Cell Line GF-D8. <i>Hamatologie Und Bluttransfusion</i> , 1998, , 363-368.	0.0	0
273	Synergistic Induction of Cell Death in Hodgkin Lymphoma Cells By the Novel PI3K Inhibitor RP6530 Combined with Brentuximab Vedotin (SGN-35) through Inhibition of Tumor Angiogenesis. <i>Blood</i> , 2015, 126, 1561-1561.	0.6	0
274	CMV-Seropositive Recipients Are at Higher Risk of CMV Reactivation and NRM after Haploidentical-SCT with PT-Cy. <i>Blood</i> , 2019, 134, 4484-4484.	0.6	0
275	Non-Myeloablative Conditioning Regimen before T-Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Lymphoma. <i>Blood</i> , 2019, 134, 4614-4614.	0.6	0
276	Abstract C052: FGF trapping impairs multiple myeloma growth through c-Myc degradation-induced mitochondrial oxidative stress. , 2019, , .		0
277	Detection of minimal residual disease in hematopoietic progenitor cell harvests: lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma. <i>American Journal of Blood Research</i> , 2012, 2, 105-12.	0.6	0
278	Effect of recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) in patients with lymphoid malignancies receiving unpurged or mafosfamide-purged autografts. <i>Behring Institute Mitteilungen</i> , 1991, , 69-74.	0.2	0
279	Selection of Philadelphia-negative progenitors from chronic myelogenous leukemia. <i>Bone Marrow Transplantation</i> , 1994, 14 Suppl 3, S45-8.	1.3	0
280	The parallel between CD45 expression and extra-medullary evolution in aggressive myeloma with high serum lactate dehydrogenase. <i>Haematologica</i> , 1998, 83, 276-9.	1.7	0